漱玉平民(301017) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 5,321,639,204.67, representing a 14.70% increase compared to CNY 4,639,809,187.20 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 114,924,330.81, a decrease of 46.88% from CNY 216,354,923.37 in 2020[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 102,254,571.67, down 55.58% from CNY 230,195,081.36 in the previous year[23]. - The basic earnings per share for 2021 was CNY 0.30, a decline of 49.15% compared to CNY 0.59 in 2020[23]. - The total assets at the end of 2021 were CNY 5,002,769,668.71, an increase of 62.67% from CNY 3,075,411,628.55 at the end of 2020[23]. - The net cash flow from operating activities for 2021 was CNY 237,526,003.92, a slight increase of 1.29% from CNY 234,499,600.43 in 2020[23]. - The weighted average return on equity for 2021 was 6.71%, down from 15.26% in 2020, reflecting a decrease of 8.55%[23]. - The company reported a significant increase in total net assets, reaching CNY 1,889,588,905.46 at the end of 2021, up 24.32% from CNY 1,519,885,872.71 at the end of 2020[23]. Store Operations - The company operated a total of 3,341 stores by the end of 2021, including 2,592 direct-operated stores and 749 franchised stores[37]. - The company opened 463 new direct stores in 2021, a significant increase of 175.60% compared to 168 new stores in the previous year[49]. - As of December 31, 2021, the company operated 2,592 direct chain stores, with 2,126 stores qualifying as "medical insurance designated pharmacies," representing 82.02% of total stores[60]. - The proportion of "院边店" (hospital-side stores) increased to 16.49% in 2021, up 422 basis points from 2020[43]. Market Trends - The retail pharmacy market in China reached CNY 469.6 billion in 2021, with a year-on-year growth of 3.21%[41]. - The overall drug retail industry in China is experiencing intensified competition, with a decrease in the average service population per store from 2,549 to 2,408[41]. - Online and offline business growth rates were 130.71% and 103.24% respectively in 2021, with online business accounting for 2.96% of total operations[43]. Revenue Breakdown - Retail revenue accounted for 89.31% of total revenue, amounting to ¥4,752,589,475.56, with a year-on-year growth of 13.40%[87]. - Wholesale revenue increased by 30.92% to ¥414,779,906.95, representing 7.79% of total revenue[87]. - The revenue from traditional Chinese and Western medicine reached ¥3,873,972,630.74, contributing 72.80% to total revenue, with a growth rate of 23.12%[87]. Strategic Initiatives - The company plans to expand its B2C and O2O sales channels to meet the growing online demand for pharmaceuticals[38]. - The company has adopted a combined procurement model to optimize supply chain efficiency, balancing centralized and regional procurement[38]. - The company is enhancing its new retail strategy by integrating online and offline channels, optimizing operational efficiency through digital transformation[82]. - The company aims to expand its market presence in northern China while solidifying its brand advantage in Shandong[74]. Human Resources and Talent Development - The company has added 3,339 employees in 2021, a 326.44% increase from the previous year[52]. - The company has established partnerships with regional professional schools to ensure a steady supply of talent[158]. - The internal multi-level training system is continuously improved, and a mobile learning platform is being developed to enhance employee competency[158]. - The company has set up a management trainee program and a young talent class to build a sustainable talent development system[158]. Corporate Governance - The company has established a complete corporate governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring independence and clarity of functions[182]. - The annual shareholders' meeting held on March 22, 2021, had a participation rate of 100%[187]. - The company completed the election of the second board of directors and the second supervisory board during the reporting period[200].